Core advantages
Production of various products from the same starting material, with outstanding cost advantages
Different from other companies in the industry that use purchased intermediate chemicals as raw materials, BTC Pharm's perfect double-helix "DNA" product chain brings the integration of production. Production starts from the basic raw materials at the source, which can effectively reduce production costs. Avoid the impact of outsourced intermediate products due to market supply shortages or price fluctuations, and ensure product quality stability. At the same time, the integration of production makes more complementary products, BTC Pharm can flexibly adjust the product structure according to the market demand, avoid risks, and maximize the company's interests. With rich product structure and proprietary co-production technology and equipment, BTC Pharm has realized the production mode of "producing various products from the same starting material", and can comprehensively utilize the by-products generated in the production process to produce products with higher economical efficiency. value of other products, reducing the overall cost of production.
Product structure with complete series and complete varieties
BTC Pharm is a world-leading DAST fine chemical manufacturer with a complete product chain and production capacity. After years of development, the product structure includes nearly 800 products in eight product series including four-membered ring, five-membered ring, six-membered ring, chain lipids, monofluoro, difluoro, and trifluoro. Most of the varieties in the product chain All can be sold separately as products, with strong market adaptability and great room for product structure adjustment and upgrading. Relying on the comprehensive production platform built by ourselves, BTC Pharm can provide a wide range of products in a wide range of categories. The product quality has high stability, which is conducive to the centralized ordering of various products required by existing customers. At the same time, the complete product structure also Facilitate purchases that attract new customers.
Strong technical reserves and R&D strength
BTC Pharm currently has 35 R&D personnel, accounting for 30% of the entire team. At the same time, BTC Pharm invests about 20% in R&D every year, and has formed a strong technical reserve, not only in the development of fluorine-containing reagents and the application of fluorine reagents, Moreover, there has been a lot of technical accumulation in the development of various substrates.
添加一句口号。